Literature DB >> 412441

Evaluation of virginiamycin in feed for treatment and retreatment of swine dysentery.

L D Olson, D E Rodabaugh.   

Abstract

Virginiamycin, fed at a concentration of 110 mg/kg of feed for 2 weeks followed by concentrations of either 27.5 or 55 mg/kg for 3 weeks, was effective in treatment and control of experimentally induced swine dysentery. However, diarrhea recurred 4 days after withdrawal of medicated feed. Subsequently, the frequency of diarrhea decreased in 3 of 4 groups retreated with virginiamycin (110 mg/kg of feed) for 5 days. Feeding of virginiamycin (110 mg/kg) for 1 week after onset of diarrhea was of little value because of the development of a more severe (augmented) form of the disease after withdrawal of medicated feed. Feeding of virginiamycin (55 mg/kg) at the time of exposure and continuing for 3 weeks (followed by intermittent retreatments of 55 mg/kg) aided in treatment and control of swine dysentery. With this regimen, a few swine developed diarrhea during initial medication, but all developed diarrhea after withdrawal fo medicated feed. Frequency of diarrhea was less after each retreatment. This was attributed to the development of immunity from the recurring diarrhea.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 412441

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  3 in total

Review 1.  Antibiotics of the virginiamycin family, inhibitors which contain synergistic components.

Authors:  C Cocito
Journal:  Microbiol Rev       Date:  1979-06

2.  Use of an enzyme-linked immunosorbent assay for detection of Treponema hyodysenteriae infection in swine.

Authors:  J C Wright; G R Wilt; R B Reed; T A Powe
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

3.  Susceptibility and resistance of ruminal bacteria to antimicrobial feed additives.

Authors:  T G Nagaraja; M B Taylor
Journal:  Appl Environ Microbiol       Date:  1987-07       Impact factor: 4.792

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.